Searched for
TIRZEPATIDE
GLP-1 drugs for weight loss Ozempic, Wegovy linked to vision loss: What is NAION, who is at risk and what symptoms should users watch for?Side effects of weight loss drugs: The makers of GLP-1 weight loss drugs such as Ozempic, Wegovy and Mounjaro must add a warning label abou...- ₹85,000 Temple: Deepinder Goyal’s wearable is a health-tech gambleDeepinder Goyal’s ₹85,000 Temple wearable aims to track real-time body performance and brain blood circulation, but its technology lacks me...
- Cipla expects US business to draw support from upcoming product pipelineCipla reported a significant decline in its consolidated net profit for the second quarter of FY27. The company's North American revenue fe...
- GLP-1 prices drop at Mochi Health, starting at $60 but what will patients actually pay?Mochi Health has reduced their prices for their GLP-1 weight loss medications. While the membership fees is entirely separate, they have me...
- ‘India’s biotech ecosystem holds tremendous promise’: Eli Lilly CEOEli Lilly has experienced significant growth, reaching a market capitalization over $1 trillion. The company aims to maintain its leadershi...
- From Jab to Pills: Novo Nordisk, Eli Lilly set to take obesity drug battle to IndiaIndia’s obesity drug market is set for a new phase as Novo Nordisk’s oral Wegovy and Eli Lilly’s oral GLP-1 orforglipron are expected to la...
- Women tip the scale as weight-loss boom reaches tier-II citiesWhile startups such as General Catalyst-backed Voy and Mumbai-based Metago are seeing higher demand from women, Elevate Now, backed by Tita...
- GLP-1 users are suing over vision loss: What does the evidence really show?Dozens of patients have taken legal action against drug manufacturers, filing personal injury lawsuits that allege they were not adequately...
- Growing peptide trend raises safety concerns among doctorsDoctors express concern over popular injectable peptides for various health benefits. They caution that established peptide medicines diffe...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- Cipla in no hurry to launch semaglutide as Yurpeak gains tractionCipla is focusing on its tirzepatide brand Yurpeak in India's obesity market. Yurpeak has become the second largest GLP-1 product since its...
- Rs 70,00,000 worth fake Mounjaro injections seized in Gurgaon; Police expose illegal weight-loss drug racket in NCRGurgaon Drug Racket: Authorities in Gurgaon have busted a major illegal pharmaceutical racket involving spurious Mounjaro KwikPen (tirzepat...
- Novo Nordisk's 'Semaglutide' gains weight against Eli Lilly in battle for market shareNovo Nordisk's diabetes and weight-loss drug semaglutide is rapidly gaining ground in India. It is now challenging Eli Lilly's tirzepatide ...
- Why did NVO stock crash over 14% today? Novo Nordisk’s weight-loss drug CagriSema misses trial goal against Eli Lilly’s TirzepatideNVO stock today: Novo Nordisk shares plummeted after its next-generation weight loss drug, CagriSema, failed to achieve non-inferiority in ...
- Cipla launches drug for obesity, diabetesCipla has launched Yurpeak, a new injectable medication for obesity and type-2 diabetes. This one-weekly therapy, tirzepatide, is now avail...
- Eli Lilly wants to be part of making a big dent in obesity and diabetes, says co's India head Winselow TuckerEli Lilly India chief Winselow Tucker said the company’s strategy of combining a strong product with ecosystem partnerships and patient edu...
- Lilly, Cipla ink distribution pact for weight loss, type 2 diabetes treatment drug YurpeakIn an exciting collaboration, Cipla and Eli Lilly have unveiled Yurpeak, a groundbreaking diabetes and weight management medication, now av...
- Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors saySemaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective ...
- Waiting for a wonder drug? The weight just got longerEli Lilly awaits India's approval to sell Tirzepatide, marketed as Mounjaro and Zepbound in the US. CEO David Ricks plans to launch the dru...
- Eli Lilly's new diabetes drug could boost the stock, says SVB SecuritiesSVB Securities believes that the new diabetes drug by Eli Lilly might be able to address patients' obesity and might lead to more significa...
Load More
